Literature DB >> 7438536

A novel eosinophil chemotactic factor derived from a histiocytic lymphoma of the central nervous system.

E J Goetzl, J Rothenberg, E L Weber, C M Sinn, K F Austen.   

Abstract

An eosinophil chemotactic activity was identified in extracts of tumour tissue and cerebrospinal fluid from a patient with a histiocytic lymphoma of the brain and spinal cord that was infiltrated extensively with eosinophils and associated with peripheral blood eosinophilia. The histiocytic lymphoma-derived eosinophils chemotactic factor, termed ECF-HL, exhibited a mol. wt of 13,000-14,000 by filtration on Sephadex G-50, was highly acidic based on its elution from a high pressure anion exchange column at pH 2 x 3 - 2 x 1, and was susceptible to inactivation by proteolytic digestion. ECF-HL was absent from extracts of control human brain tissue, glioblastomas, other lymphomas and a variety of carcinomas that lacked an accumulation of eosinophils. Partially purified ECF-HL had no chemokinetic activity, but rendered eosinophils unresponsive to other chemotactic factors. Thus ECF-HL is structurally and functionally distinct from other recognized peptides that are preferentially chemotactic for eosinophils.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438536      PMCID: PMC1536990     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Eosinophil chemotaxis of supernatants from cultured Hodgkin's lymph node cells.

Authors:  A B Kay; J M McVie; A E Stuart; A Krajewski; L W Turnbull
Journal:  J Clin Pathol       Date:  1975-06       Impact factor: 3.411

2.  Rapidly fatal familial histiocytosis associated with eosinophilia and primary immunological deficiency.

Authors:  R F Barth; G G Vergara; S K Khurana; J T Lowman; J B Beckwith
Journal:  Lancet       Date:  1972-09-09       Impact factor: 79.321

3.  Eosinophila and metastatic carcinoma.

Authors:  M V Viola; E Chung; M G Mukhopadhyay
Journal:  Med Ann Dist Columbia       Date:  1972-01

4.  Preformed eosinophil chemotactic factor of anaphylaxis (ECF-A).

Authors:  S I Wasserman; E J Goetzl; K F Austen
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

5.  Tumor-associated eosinophilotactic factor.

Authors:  S I Wasserman; E J Goetzl; L Ellman; K F Austen
Journal:  N Engl J Med       Date:  1974-02-21       Impact factor: 91.245

6.  Malignant histiocytosis with cutaneous involvement and eosinophilia.

Authors:  K T Liao; J Rosai; K Daneshbod
Journal:  Am J Clin Pathol       Date:  1972-04       Impact factor: 2.493

7.  Eosinophilia following radiation therapy.

Authors:  F M Muggia; N A Ghossein; H Wohl
Journal:  Oncology       Date:  1973       Impact factor: 2.935

8.  Malignant lymphoma presenting with a high eosinophilia, eosinophilic pleurisy, and pericrditis.

Authors:  A H Henderson; G Mejia
Journal:  Thorax       Date:  1969-01       Impact factor: 9.139

9.  Purification and synthesis of eosinophilotactic tetrapeptides of human lung tissue: identification as eosinophil chemotactic factor of anaphylaxis.

Authors:  E J Goetzl; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

10.  Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis.

Authors:  E J Goetzl; K F Austen
Journal:  J Exp Med       Date:  1976-12-01       Impact factor: 14.307

View more
  3 in total

1.  Diffuse abdominal epithelioid mesothelioma in a cow.

Authors:  C A Girard; A Cécyre
Journal:  Can Vet J       Date:  1995-07       Impact factor: 1.008

Review 2.  The human eosinophil: roles in host defense and tissue injury.

Authors:  P F Weller; E J Goetzl
Journal:  Am J Pathol       Date:  1980-09       Impact factor: 4.307

3.  Presence of factors chemotactic for granulocytes in hypereosinophilic syndrome sera: relation with alterations in eosinophil migration.

Authors:  P Gosset; L Prin; M Capron; C Auriault; A B Tonnel; A Capron
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.